Physician profile
Luis J Lopez
NPI 1346342201
$7,842.26
in general payments reported to CMS, 2019-2025
29 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $368 · 2021: $950 · 2022: $1,157 · 2023: $1,702 · 2024: $1,318 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,343 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.52 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,823.94 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,124.16 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $823.31 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $316.67 | 2022-2023 | |
| Vivus LLC | $244.68 | 2023-2025 | Pancreaze |
| Gilead Sciences, INC. | $231.54 | 2019-2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $220.07 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $217.16 | 2019-2024 | |
| Celgene Corporation | $181.82 | 2021-2024 | Zeposia |
| Ambu INC. | $178.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $177.75 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $168.50 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $165.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Ethicon US, LLC | $137.45 | 2019-2020 | |
| Allergan, INC. | $122.75 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $122.13 | 2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $109.31 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $108.32 | 2019 | |
| Lumendi LLC | $82.37 | 2021 | |
| Celltrion USA INC. | $69.21 | 2025 | Vegzelma |
| Lucid Diagnostics INC. | $63.79 | 2021 | |
| Aimmune Therapeutics, INC. | $54.41 | 2024-2025 | Zenpep |
| Abbott Laboratories | $38.45 | 2021-2022 | |
| Pfizer INC. | $23.79 | 2025 | |
| Apollo Endosurgery US INC | $13.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| Evoke Pharma, INC. | $11.47 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.